AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14535872 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-susceptible strains
Number of subjects: 287
Study 14535872 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-resistant strains
Number of subjects: 287
Study 10944140 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotaped initial consultation
Number of subjects: 201
Study 10944140 — intervention group
Group type: COMPARATOR
Intervention: No audiotaped initial consultation (control group)
Number of subjects: 201
Study 8558189 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 over 3 hours, repeated every 3 weeks for a maximum of nine cycles
Number of subjects: 51
Study 1385682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.03% (21 micrograms per nostril)
Number of subjects: 140
Study 1385682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.03% (42 micrograms per nostril)
Number of subjects: 140
Study 1385682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 6425480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with total parenteral nutrition (120% of estimated energy requirements, 3.75% or 22.5% as lipid, amino acids 2.5 gm/120 kcal)
Number of subjects: 11
Study 6425480 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-parenteral nutrition period
Number of subjects: 11
Study 6425480 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements before intervention)
Number of subjects: 11
Study 31077726 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable cardioverter-defibrillator (WCD)
Number of subjects: 0
Study 29514712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg q4w
Number of subjects: 122
Study 29514712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg q2w
Number of subjects: 122
Study 26271449 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 100
Study 26271449 — intervention group
Group type: COMPARATOR
Intervention: Control (deflated cuff placed on upper arm for 30 min)
Number of subjects: 100
Study 24434117 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (20 g/d for 7 d)
Number of subjects: 16
Study 24434117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22429800 — intervention group
Group type: EXPERIMENTAL
Intervention: Semuloparin
Number of subjects: 1150
Study 22429800 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1150
Study 20181654 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (150 mg to 250 mg po BID) as add-on therapy to standard care for up to 10 months
Number of subjects: 12
Study 20181654 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (10-100 mg kg(‐1))
Number of subjects: 12
Study 20181654 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (10-100 mg kg(‐1))
Number of subjects: 12
Study 20181654 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline and doxycycline
Number of subjects: 12
Study 20181654 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 12
Study 18820095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency maintenance exercise (1 time per week)
Number of subjects: 36
Study 18820095 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency maintenance exercise (4 times per week)
Number of subjects: 36
Study 16019358 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE) alone
Number of subjects: 35
Study 16019358 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE alone
Number of subjects: 35
Study 16019358 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE
Number of subjects: 35
Study 16019358 — intervention group
Group type: COMPARATOR
Intervention: Progestogens (medroxyprogesterone acetate, desogestrel, norethisterone)
Number of subjects: 35
Study 11573655 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (ACEI) for 2 days, n=7
Number of subjects: 14
Study 11573655 — intervention group
Group type: COMPARATOR
Intervention: Control group, n=7
Number of subjects: 14
Study 9776034 — intervention group
Group type: EXPERIMENTAL
Intervention: Periosteal barrier
Number of subjects: 28
Study 9776034 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap
Number of subjects: 28
Study 8072049 — intervention group
Group type: EXPERIMENTAL
Intervention: High-reward condition (four stars per prize)
Number of subjects: 0
Study 8072049 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent reinforcers available (all clients)
Number of subjects: 0
Study 8072049 — intervention group
Group type: EXPERIMENTAL
Intervention: High-reward clients
Number of subjects: 0
Study 8072049 — intervention group
Group type: COMPARATOR
Intervention: Low-reward clients
Number of subjects: 0
Study 8072049 — intervention group
Group type: COMPARATOR
Intervention: Delayed-reward clients
Number of subjects: 0
Study 3289379 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(R)‐15‐methyl prostaglandin E2 (Arbacet) (10 micrograms, 0.5 h before each meal and at bedtime)
Number of subjects: 20
Study 3289379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31859121 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making and patient engagement (SDM-PE) program in addition to standard treatment
Number of subjects: 0
Study 31859121 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 31859121 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making and patient engagement (SDM-PE) program
Number of subjects: 0
Study 30836052 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing bullying in terms of resilience
Number of subjects: 0
Study 30836052 — intervention group
Group type: COMPARATOR
Intervention: Framing bullying with negative psychosocial consequences
Number of subjects: 0
Study 28001147 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with 2 g of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032
Number of subjects: 66
Study 28001147 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (same product without probiotics)
Number of subjects: 66
Study 28001147 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 66
Study 26414563 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric titration method (CTM)
Number of subjects: 167
Study 26414563 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 167
Study 24184430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) - exposure in situ with therapist (T+)
Number of subjects: 146
Study 24184430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) - exposure on their own following therapist preparation (T-)
Number of subjects: 146
Study 24184430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both variations of CBT
Number of subjects: 146
Study 21349747 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thrombotics
Number of subjects: 482
Study 21349747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs
Number of subjects: 482
Study 21349747 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive drugs
Number of subjects: 482
Study 19129289 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive integrated care (PIC)
Number of subjects: 40
Study 19129289 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 40
Study 17596917 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 587
Study 15026849 — intervention group
Group type: EXPERIMENTAL
Intervention: Data mining methods for predicting IVS thickness clusters ('small' or 'large') using a clusterbase/rulebase combination.
Number of subjects: 63
Study 11297240 — intervention group
Group type: EXPERIMENTAL
Intervention: Edatrexate 40 mg/m2 weekly with cisplatin 120 mg/m2 every 4 weeks (Schedule A)
Number of subjects: 39
Study 11297240 — intervention group
Group type: EXPERIMENTAL
Intervention: Edatrexate 80 mg/m2 biweekly with cisplatin 60 mg/m2 every 2 weeks (Schedule B)
Number of subjects: 39
Study 11877227 — intervention group
Group type: EXPERIMENTAL
Intervention: Hh-treated eyes (n = 46)
Number of subjects: 78
Study 11877227 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (n = 42)
Number of subjects: 78
Study 8068835 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible maximum likelihood methods for assessing joint effects in case-control studies.
Number of subjects: 0
Study 3187701 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain (Discase)
Number of subjects: 173
Study 3187701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cysteine‐edetate‐iothalamate: CEI)
Number of subjects: 173
Study 29559386 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic deep-brain stimulation (STN DBS)
Number of subjects: 12
Study 28259171 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity CBT intervention
Number of subjects: 323
Study 28259171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity CBT intervention
Number of subjects: 323
Study 28259171 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 323
Study 28259171 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CBT interventions
Number of subjects: 323
Study 26080804 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond consumption (85 g/day) added to a National Cholesterol Education Program (NCEP) Step 1 diet (ALM) for 6 weeks
Number of subjects: 45
Study 26080804 — intervention group
Group type: COMPARATOR
Intervention: Control NCEP Step 1 diet absent nuts (CON)
Number of subjects: 45
Study 24517062 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiju Dihuang Oral Liquid (QDOL), 10 mL twice daily for 2 weeks, for a total of 6 courses.
Number of subjects: 200
Study 24517062 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control group).
Number of subjects: 200
Study 24517062 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment system for preeclampsia.
Number of subjects: 200
Study 24517062 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure method.
Number of subjects: 200
Study 21942915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day
Number of subjects: 0
Study 21942915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19428189 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) readiness
Number of subjects: 267
Study 19428189 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of Problems (PP)
Number of subjects: 267
Study 19428189 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking Action (TA)
Number of subjects: 267
Study 17076604 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg 1 hour before surgery and 12 hours after the first dose
Number of subjects: 20
Study 17076604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg 1 hour before surgery and 8 hours after the first dose
Number of subjects: 20
Study 17076604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17076604 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 20
Study 14756620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral self-help treatment
Number of subjects: 109
Study 14756620 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 109
Study 11319249 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses
Number of subjects: 30
Study 11319249 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft insoles
Number of subjects: 30
Study 11319249 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study 8732400 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 29
Study 8732400 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 29
Study 2191854 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 253
Study 2191854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 364037 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D dietary supplement
Number of subjects: 46
Study 364037 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 46
Study 31712967 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative intervention to prevent youth problem gambling
Number of subjects: 111
Study 31712967 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study 31129065 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting antiplatelet therapy
Number of subjects: 525
Study 31129065 — intervention group
Group type: COMPARATOR
Intervention: Avoiding antiplatelet therapy
Number of subjects: 525
Study 28756569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic corticosteroids (administered three times every other day)
Number of subjects: 35
Study 28756569 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids
Number of subjects: 35
Study 25801204 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate interventions to reduce tobacco use, increase physical activity, and improve dietary intake delivered in intervention areas.
Number of subjects: 15726
Study 25801204 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 15726
Study 25274428 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-MLR 80 mg once daily
Number of subjects: 26
Study 25274428 — intervention group
Group type: COMPARATOR
Intervention: IR methylphenidate 25 mg three times daily
Number of subjects: 26
Study 22342396 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day albendazole therapy
Number of subjects: 105
Study 22342396 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-day albendazole therapy
Number of subjects: 105
Study 22342396 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 105
Study 22342396 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole therapy (both durations)
Number of subjects: 105
Study 22342396 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure recurrence
Number of subjects: 105
Study 20837499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 25
Study 18055663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 60
Study 18055663 — intervention group
Group type: COMPARATOR
Intervention: Self-help condition
Number of subjects: 60
Study 15623768 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasses only
Number of subjects: 177
Study 15623768 — intervention group
Group type: EXPERIMENTAL
Intervention: Full treatment with glasses and occlusion
Number of subjects: 177
Study 15623768 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 177
Study 11854583 — intervention group
Group type: EXPERIMENTAL
Intervention: Injured subjects (MBI)
Number of subjects: 84
Study 11854583 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 84
Study 10197852 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week course of 300 mg of cyproterone acetate daily followed by surgery (CPA)
Number of subjects: 213
Study 10197852 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy alone (Sx)
Number of subjects: 213
Study 8879348 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (mean daily dose of 13 mg)
Number of subjects: 50
Study 1521676 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivida (500 mg/day for 90 days)
Number of subjects: 30
Study 1521676 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg/day for 90 days)
Number of subjects: 30
Study 6097571 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g wheat bran
Number of subjects: 23
Study 6097571 — intervention group
Group type: COMPARATOR
Intervention: 20 g Rice Krispies (low-fibre food)
Number of subjects: 23
Study 6097571 — intervention group
Group type: COMPARATOR
Intervention: Zinc alone
Number of subjects: 23
Study 30768486 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms
Number of subjects: 611
Study 30768486 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 611
Study 29808537 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural taping device used at home for 4 weeks
Number of subjects: 24
Study 29808537 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 27573987 — intervention group
Group type: EXPERIMENTAL
Intervention: New presentation strategy for HAI data
Number of subjects: 61
Study 27573987 — intervention group
Group type: COMPARATOR
Intervention: Current CMS presentation strategy for HAI data
Number of subjects: 61
Study 24953249 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) for 60 minutes before 30 minutes of physical therapy
Number of subjects: 16
Study 24953249 — intervention group
Group type: COMPARATOR
Intervention: Control group with 30 minutes of physical therapy alone
Number of subjects: 16
Study 22577067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation plus physical rehabilitation
Number of subjects: 0
Study 22577067 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Number of subjects: 0
Study 22577067 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19454639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) alone
Number of subjects: 160
Study 19454639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) plus 10 mg/d of zolpidem
Number of subjects: 160
Study 19454639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (CBT plus zolpidem) followed by CBT alone
Number of subjects: 160
Study 19454639 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) alone during maintenance
Number of subjects: 160
Study 19454639 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) plus zolpidem during maintenance
Number of subjects: 160
Study 17488903 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection after 6 months of pregnancy
Number of subjects: 1190
Study 17488903 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection before 4 months of pregnancy
Number of subjects: 1190
Study 15219195 — intervention group
Group type: EXPERIMENTAL
Intervention: GPIIb-IIIa antagonists (abciximab)
Number of subjects: 50
Study 15219195 — intervention group
Group type: COMPARATOR
Intervention: Control group (STEMI patients treated by PTCA without GPIIb-IIIa antagonist)
Number of subjects: 50
Study 12217810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose anti-thymocyte globulin (ATG) as first-line treatment within 14 days of diagnosis
Number of subjects: 28
Study 12217810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose anti-thymocyte globulin (ATG) as second-line therapy more than 14 days after diagnosis
Number of subjects: 28
Study 12217810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose anti-thymocyte globulin (ATG) early treatment group
Number of subjects: 28
Study 12217810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose anti-thymocyte globulin (ATG) late treatment group
Number of subjects: 28
Study 12217810 — intervention group
Group type: COMPARATOR
Intervention: Concurrent control group (not treated with ATG)
Number of subjects: 28
Study 10354716 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids treatment in patients with idiopathic pulmonary fibrosis and avian fancier's lung
Number of subjects: 188
Study 10354716 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids treatment in sarcoidosis patients
Number of subjects: 188
Study 10354716 — intervention group
Group type: COMPARATOR
Intervention: No treatment in pulmonary fibrosis patients
Number of subjects: 188
Study 10354716 — intervention group
Group type: COMPARATOR
Intervention: No treatment in sarcoidosis patients
Number of subjects: 188
Study 10354716 — intervention group
Group type: COMPARATOR
Intervention: No treatment in avian fancier's lung patients
Number of subjects: 188
Study 10499883 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 1 mg before each meal
Number of subjects: 25
Study 10499883 — intervention group
Group type: COMPARATOR
Intervention: Fixed-meal regimen
Number of subjects: 25
Study 10499883 — intervention group
Group type: COMPARATOR
Intervention: Mixed-meal regimens
Number of subjects: 25
Study 10499883 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 25
Study 2374529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole for 21 days
Number of subjects: 12
Study 2374529 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy with cotrimoxazole followed by pentamidine inhalation for 21 days
Number of subjects: 12
Study 668784 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chlordiazepoxide hydrochloride (50 mg)
Number of subjects: 42
Study 668784 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular chlordiazepoxide hydrochloride (50 mg)
Number of subjects: 42
Study 668784 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chlordiazepoxide hydrochloride (100 mg)
Number of subjects: 42
Study 668784 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular chlordiazepoxide hydrochloride (100 mg)
Number of subjects: 42
Study 31982648 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based prognostic algorithms and behavioral nudges to prompt oncologists to have serious illness conversations (SICs)
Number of subjects: 0
Study 31982648 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29771390 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke Free Intervention (SFI)
Number of subjects: 481
Study 29771390 — intervention group
Group type: COMPARATOR
Intervention: Usual education (control)
Number of subjects: 481
Study 29771390 — intervention group
Group type: EXPERIMENTAL
Intervention: SFI
Number of subjects: 481